GH Research PLC (NASDAQ:GHRS - Get Free Report) shares fell 1% during mid-day trading on Thursday . The stock traded as low as $7.93 and last traded at $8.25. 38,773 shares were traded during mid-day trading, a decline of 51% from the average session volume of 79,565 shares. The stock had previously closed at $8.33.
Analyst Ratings Changes
Several brokerages have issued reports on GHRS. JMP Securities restated a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of GH Research in a report on Thursday, September 5th.
View Our Latest Research Report on GH Research
GH Research Trading Down 2.8 %
The business's fifty day simple moving average is $8.09 and its 200-day simple moving average is $10.55. The firm has a market cap of $421.43 million, a P/E ratio of -12.09 and a beta of 0.79.
GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. As a group, research analysts expect that GH Research PLC will post -0.89 earnings per share for the current fiscal year.
Institutional Investors Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP raised its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 80.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,310,563 shares of the company's stock after acquiring an additional 1,471,946 shares during the quarter. GH Research comprises approximately 9.1% of Lynx1 Capital Management LP's portfolio, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Further Reading
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
